NCT06879145
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
At risk: Primary endpoint(s) modified, enrollment reduced 12%.
See at-risk trials from Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 5 more changesShow less
- Eligibility criteria expanded, about 15 words
- Enrollment reduced: 840 → 740 participants
- Interventions modified
- Trial arms changed: 1 → 2
- Secondary endpoints revised (8)
- Notable Eligibility criteria revisedv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of May 2025 to Apr 25, 2025
- Site details revised
- Notable Start date: Mar 31, 2025 to May 2025v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Phase II: pCR evaluated by researchers
Timeframe: 3 months after the last subject underwent RC+PLD surgery.
Phase III: EFS assessed by BICR
Timeframe: 5 years after the first medication of the last subject.
Recommended Phase 3 Dose (RP3D)
Timeframe: 3 months after MIBC surgery.
Secondary (8)
ORR
DCR
pCR
EFS
DFS
Show 3 moreShow less
OS
Pathological downstaging (pDS)
AE
Arms and interventions
SHR-A2102 + Adebrelimab GroupExperimental
Treatment with SHR-A2102 in combination with a fixed dose of Adebrelimab.
Preoperative Chemotherapy GroupActive comparator
Preoperative chemotherapy with gemcitabine and cisplatin, and postoperative nivolumab treatment for patients with high-risk recurrence.
Drugs: SHR-A2102, Adebrelimab, Gemcitabine Hydrochloride for Injection, Cisplatin Injection, Nivolumab Injection
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China